What does this research mean for the field?

Canadian AML diagnostic laboratories exhibit varied reporting practices and turn-around-time targets for genomic testing, but share a strong consensus on the need to reduce turn-around times and establish national laboratory guidelines. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To characterize the current landscape of diagnostic testing, reporting practices, and turnaround time targets for adult acute myeloid leukemia across Canadian laboratories.

August 27, 2026Current OncologyOpen Access

Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice

View Full Paper

Ask AI

Bookmark

Authors

TLTina Yu Xuan Luo SUSila Usta EMEric McGinnis

Discussion

Member takes

Overview

Cross-sectional survey reveals diagnostic biomarker variation and turnaround time priorities in hematology laboratories, indicating widespread demand for standardized national guidelines.

Key Points

To characterize the current landscape of diagnostic testing, reporting practices, and turnaround time targets for adult acute myeloid leukemia across Canadian laboratories.
Administered a cross-sectional online survey in September 2024 to laboratory hematology leadership (N = 18) representing 16 laboratories across 10 Canadian provinces.
Turnaround time (TAT) targets were predominantly set via internal consensus (62%) or external guidelines (44%), with TAT reduction marked as a top priority by 56% of laboratories.
Rapid testing (5-day TAT) was frequently available for FLT3-ITD (69%), FLT3-TKD (56%), and NPM1 (56%), but was limited for IDH1 and TP53.
Respondents expressed strong interest in shared measurable residual disease assay validation (56%) and unanimous support for establishing national laboratory consensus guidelines.

Cite This Study

Luo et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe9c910c91c1e92621bab https://doi.org/10.3390/curroncol33090505

View Full Paper

Ask AI

Bookmark

August 27, 2026Current OncologyOpen Access

Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice

View Full Paper

Ask AI

Bookmark

Authors

TLTina Yu Xuan Luo SUSila Usta EMEric McGinnis

Discussion

Member takes

Overview

Cross-sectional survey reveals diagnostic biomarker variation and turnaround time priorities in hematology laboratories, indicating widespread demand for standardized national guidelines.

Key Points

To characterize the current landscape of diagnostic testing, reporting practices, and turnaround time targets for adult acute myeloid leukemia across Canadian laboratories.
Administered a cross-sectional online survey in September 2024 to laboratory hematology leadership (N = 18) representing 16 laboratories across 10 Canadian provinces.
Turnaround time (TAT) targets were predominantly set via internal consensus (62%) or external guidelines (44%), with TAT reduction marked as a top priority by 56% of laboratories.
Rapid testing (5-day TAT) was frequently available for FLT3-ITD (69%), FLT3-TKD (56%), and NPM1 (56%), but was limited for IDH1 and TP53.
Respondents expressed strong interest in shared measurable residual disease assay validation (56%) and unanimous support for establishing national laboratory consensus guidelines.

Cite This Study

Luo et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe9c910c91c1e92621bab https://doi.org/10.3390/curroncol33090505

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark